Recombinant Anti-BCRP/ABCG2 antibody [EPR2099(2)] (ab108312)
![Western blot - Anti-BCRP/ABCG2 antibody [EPR2099(2)] (ab108312)](https://www.abcam.com/ps/products/108/ab108312/Images/ab108312-120866-anti-bcrp-abcg2-antibody-epr20992-western-blot.jpg "Western blot - Anti-BCRP/ABCG2 antibody [EPR2099(2)] (ab108312)")
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR2099(2)] to BCRP/ABCG2
- Suitable for: WB
- Reacts with: Human
Overview
-
Product name
Anti-BCRP/ABCG2 antibody [EPR2099(2)]
See all BCRP/ABCG2 primary antibodies -
Description
Rabbit monoclonal [EPR2099(2)] to BCRP/ABCG2 -
Host species
Rabbit -
Tested Applications & Species
See all applications and species dataApplication Species WB Human
-
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- Human fetal liver, JAR, 293T, HepG2, and Human placenta lysates.
-
General notes
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
pH: 7.20
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 50% Tissue culture supernatant -
Concentration information loading... -
Purity
Tissue culture supernatant -
Clonality
Monoclonal -
Clone number
EPR2099(2) -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab108312 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Tested applications are guaranteed to work and covered by our Abpromise guarantee.
Predicted to work for this combination of applications and species but not guaranteed.
Does not work for this combination of applications and species.
| Application | Species |
|---|---|
| WB |
Human
|
| Application | Abreviews | Notes |
|---|---|---|
| WB |
1/1000 - 1/10000. Predicted molecular weight: 72 kDa.
|
| Notes |
|---|
|
WB
1/1000 - 1/10000. Predicted molecular weight: 72 kDa. |
Target
-
Function
Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from the brain. May be involved in brain-to-blood efflux. Appears to play a major role in the multidrug resistance phenotype of several cancer cell lines. When overexpressed, the transfected cells become resistant to mitoxantrone, daunorubicin and doxorubicin, display diminished intracellular accumulation of daunorubicin, and manifest an ATP-dependent increase in the efflux of rhodamine 123. -
Tissue specificity
Highly expressed in placenta. Low expression in small intestine, liver and colon. -
Sequence similarities
Belongs to the ABC transporter superfamily. ABCG family. Eye pigment precursor importer (TC 3.A.1.204) subfamily.
Contains 1 ABC transmembrane type-2 domain.
Contains 1 ABC transporter domain. -
Post-translational
modificationsGlycosylation-deficient ABCG2 is normally expressed and functional. -
Cellular localization
Cell membrane. - Information by UniProt
-
Database links
- Entrez Gene: 9429 Human
- Omim: 603756 Human
- SwissProt: Q9UNQ0 Human
- Unigene: 480218 Human
-
Alternative names
- ABC transporter antibody
- ABC15 antibody
- ABCG 2 antibody
see all
Images
-
Western blot - Anti-BCRP/ABCG2 antibody [EPR2099(2)] (ab108312)All lanes : Anti-BCRP/ABCG2 antibody [EPR2099(2)] (ab108312) at 1/1000 dilution
Lane 1 : Human fetal liver lysate
Lane 2 : JAR lysate
Lane 3 : 293T lysate
Lane 4 : HepG2 lysate
Lane 5 : Human placenta lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 72 kDa -
![Anti-BCRP/ABCG2 antibody [EPR2099(2)] (ab108312)](https://www.abcam.com/ps/products/108/ab108312/Images/ab108312-2-benefits-of-recombinant-antibodies.png)
Anti-BCRP/ABCG2 antibody [EPR2099(2)] (ab108312)
Datasheets and documents
-
SDS download
-
Datasheet download
References (11)
ab108312 has been referenced in 11 publications.
- Gomes I et al. Expression of receptor activator of NFkB (RANK) drives stemness and resistance to therapy in ER+HER2- breast cancer. Oncotarget 11:1714-1728 (2020). PubMed: 32477461
- Ding Y et al. Levistolide A synergistically enhances doxorubicin-induced apoptosis of k562/dox cells by decreasing MDR1 expression through the ubiquitin pathway. Oncol Rep 41:1198-1208 (2019). PubMed: 30483812
- Wang X et al. Fatty acid receptor GPR120 promotes breast cancer chemoresistance by upregulating ABC transporters expression and fatty acid synthesis. EBioMedicine 40:251-262 (2019). PubMed: 30738829
- Simbulan-Rosenthal CM et al. CD133 Is Associated with Increased Melanoma Cell Survival after Multikinase Inhibition. J Oncol 2019:6486173 (2019). PubMed: 31379943
- Nakano T et al. Hepatitis C virus core protein triggers abnormal porphyrin metabolism in human hepatocellular carcinoma cells. PLoS One 13:e0198345 (2018). PubMed: 29856826